Evidence map›Paper›PMID 37167363›Full record

ReviewCirculation research2023

COVID-19, Myocarditis and Pericarditis.

DeLisa Fairweather, Danielle J Beetler, Damian N Di Florio, Nicolas Musigk, Bettina Heidecker, Leslie T Cooper

Open access · hybridAbstract readReview
In one paragraph

Review in Circulation research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers.

0numbers the graph read from it
0cells of the map it votes in
106citing papers in PubMed
35.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

106 citing papers in PubMed, 162 citations in OpenAlex.

  1. Review
  2. The Impact of COVID-19 Infection and Vaccination on Myocarditis Incidence: A Comparative Analysis of Pre-, Peri-, and Post-Pandemic Eras.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. "Bridging the clinical, molecular and genetic perspectives on myocarditis in post-COVID-19 era".International journal of cardiology. Cardiovascular risk and prevention · 2026
    Review
  8. Article
  9. Five-year cardiovascular outcomes following COVID-19-associated carditis.Clinical research in cardiology : official journal of the German Cardiac Society · 2026
    Article
  10. Article
  11. Review
  12. Zinc: a metallic shield against cardiac inflammation.Metallomics : integrated biometal science · 2026
    Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Observational
  18. Article
  19. Article
  20. Article

46 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

DeLisa Fairweather *Department of Cardiovascular Medicine (D.F., D.J.B., D.N.D., L.T.C.), Mayo Clinic, Jacksonville, FL.ORCID 0000-0003-3093-1810
Danielle J Beetler *Department of Cardiovascular Medicine (D.F., D.J.B., D.N.D., L.T.C.), Mayo Clinic, Jacksonville, FL.
Damian N Di FlorioDepartment of Cardiovascular Medicine (D.F., D.J.B., D.N.D., L.T.C.), Mayo Clinic, Jacksonville, FL.
Nicolas MusigkDeutsches Herzzentrum der Charité, Berlin, Germany (N.M., B.H.).
Bettina HeideckerDeutsches Herzzentrum der Charité, Berlin, Germany (N.M., B.H.).ORCID 0000-0002-3811-7920
Leslie T CooperDepartment of Cardiovascular Medicine (D.F., D.J.B., D.N.D., L.T.C.), Mayo Clinic, Jacksonville, FL.ORCID 0000-0003-1002-3313
Jacksonville College · USDeutsches Herzzentrum der Charité · DEJohns Hopkins University · US

Funding

CTSA Administrative Supplement for Informatics Core: A novel AI/ML system to predict respiratory failure and ARDS in Covid-19 patientsUL1TR002556 · NCATS · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI KELLER, MARLA J, KIM, MIMI Y · 2018 to 2022
$26.7M
NRSA Training CoreTL1TR002380 · NCATS · MAYO CLINIC ROCHESTER · PI Felicity T. B. Enders, ANTHONY John WINDEBANK · 2017 to 2026
$6.0M
Role of mitochondrial extracellular vesicles in CVB3 myocarditis by sexR01HL164520 · NHLBI · MAYO CLINIC JACKSONVILLE · PI FAIRWEATHER, DELISA · 2022 to 2025
$3.0M
Role of viral mitophagosomes in driving sex differences in myocarditisR21AI145356 · NIAID · MAYO CLINIC JACKSONVILLE · PI FAIRWEATHER, DELISA, SIN, JON · 2019 to 2020
$463k
Adipose-derived biogenic nanoparticles for treatment of myocarditis/DCM(MPDPI)R21AI152318 · NIAID · MAYO CLINIC JACKSONVILLE · PI FAIRWEATHER, DELISA, WOLFRAM, JOY · 2020 to 2021
$430k
Sex differences in exercise-induced mitochondrial function during viral myocarditisR21AI154927 · NIAID · MAYO CLINIC JACKSONVILLE · PI FAIRWEATHER, DELISA · 2020 to 2021
$403k
NCATS NIH HHS TL1 TR002380NCATS NIH HHS UL1 TR002556NHLBI NIH HHS R01 HL164520NIAID NIH HHS R21 AI145356NIAID NIH HHS R21 AI152318NIAID NIH HHS R21 AI154927
6 · The paper itself

Abstract

Viral infections are a leading cause of myocarditis and pericarditis worldwide, conditions that frequently coexist. Myocarditis and pericarditis were some of the early comorbidities associated with SARS-CoV-2 infection and COVID-19. Many epidemiologic studies have been conducted since that time concluding that SARS-CoV-2 increased the incidence of myocarditis/pericarditis at least 15× over pre-COVID levels although the condition remains rare. The incidence of myocarditis pre-COVID was reported at 1 to 10 cases/100 000 individuals and with COVID ranging from 150 to 4000 cases/100 000 individuals. Before COVID-19, some vaccines were reported to cause myocarditis and pericarditis in rare cases, but the use of novel mRNA platforms led to a higher number of reported cases than with previous platforms providing new insight into potential pathogenic mechanisms. The incidence of COVID-19 vaccine-associated myocarditis/pericarditis covers a large range depending on the vaccine platform, age, and sex examined. Importantly, the findings highlight that myocarditis occurs predominantly in male patients aged 12 to 40 years regardless of whether the cause was due to a virus-like SARS-CoV-2 or associated with a vaccine-a demographic that has been reported before COVID-19. This review discusses findings from COVID-19 and COVID-19 vaccine-associated myocarditis and pericarditis considering the known symptoms, diagnosis, management, treatment, and pathogenesis of disease that has been gleaned from clinical research and animal models. Sex differences in the immune response to COVID-19 are discussed, and theories for how mRNA vaccines could lead to myocarditis/pericarditis are proposed. Additionally, gaps in our understanding that need further research are raised.

Indexed as

COVID-19COVID-19 VaccinesMyocarditisPericarditisFemaleHumansMaleSARS-CoV-2COVID-19 VaccinesCOVID-19 vaccinesmodels, animalmRNA vaccinessex characteristicsvaccines

Identifiers

PMID37167363
PMCPMC10171304
OpenAlexW4376128883

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.